Wegovy semaglutide

Without insurance, Wegovy's list price is approximately $1,349 per 28-day supply, regardless of dose. Novo Nordisk runs a self-pay program (NovoCare) that lowers the cost to about $499/month for eligible patients paying entirely out-of-pocket. Some telehealth services bundle Wegovy with clinical care at competitive rates; expect $500-800/month all-in including the medication itself. Compounded semaglutide (a different product, formulated by 503A/503B compounding pharmacies during shortages) historically ran $200-400/month but its legal status has narrowed as Novo Nordisk's branded supply has normalized. A standard pharmacy GoodRx coupon typically does not produce a meaningful Wegovy discount — savings come from manufacturer programs or vetted telehealth partners.

Wegovy coverage depends on three things: your insurance plan's formulary, your BMI and comorbidities, and whether your plan covers weight-loss drugs at all. Many commercial plans require BMI ≥30 (or ≥27 with a weight-related comorbidity like hypertension or sleep apnea) and prior authorization. Medicare does not currently cover anti-obesity medications including Wegovy, though coverage has been proposed under the Treat and Reduce Obesity Act. Medicaid coverage varies by state. If denied, your prescriber can submit an appeal documenting medical necessity. Even with coverage, prior authorization can take 1-4 weeks; many patients use NovoCare self-pay in parallel during the wait.

At list price, Zepbound is slightly cheaper than Wegovy (~$1,060 vs ~$1,349/month). For cash-pay patients, Lilly's self-pay vial program ($349-$549/month for Zepbound) tends to undercut Novo's NovoCare self-pay program ($499/month for Wegovy) at lower doses. At higher Zepbound doses, the gap narrows. Insurance coverage patterns are similar; the better choice for any individual depends on which drug their formulary covers preferentially.

Four practical strategies: (1) NovoCare self-pay program — drops list price to ~$499/month if you qualify (typically no insurance or insurance that won't cover it). (2) Insurance appeal — if denied, your prescriber can submit a letter of medical necessity documenting BMI and comorbidities. Success rates are meaningful when documentation is solid. (3) Telehealth bundles — some services include the medication, clinical care, and follow-up at a flat monthly rate that may beat retail. (4) Formulary alternative — if your plan covers a different GLP-1 (Zepbound, Saxenda, or Ozempic off-label for weight), that may be more affordable than fighting for Wegovy.

Medicare currently covers GLP-1 medications only when prescribed for FDA-approved indications other than weight loss. Ozempic, Mounjaro, and Trulicity are covered for type 2 diabetes when medically indicated. Wegovy and Zepbound — both FDA-approved specifically for chronic weight management — are not covered by Medicare. The Treat and Reduce Obesity Act has been introduced in Congress to change this, but as of 2026 it has not become law. Medicare Advantage plans sometimes offer expanded coverage; check your specific plan documents. Medicaid coverage varies significantly by state.

GLP-1 receptor agonists mimic glucagon-like peptide-1, a gut hormone released after eating. They work through three main pathways: (1) Slowing gastric emptying — food stays in the stomach longer, prolonging fullness. (2) Suppressing appetite in the brain — they reduce the constant 'food noise' many patients describe, making it easier to eat smaller portions and skip snacks. (3) Improving insulin response — they enhance glucose-dependent insulin release, which helps with blood sugar control. Tirzepatide (Mounjaro/Zepbound) additionally activates GIP receptors, producing stronger appetite suppression and weight loss than GLP-1 alone in head-to-head trials.